How did TRIB's Q4 forecast compare to past surprises?

Trinity Biotech's (TRIB) Q4 forecast, as indicated by the estimated EPS and revenue, projected a significant decline compared to the past surprises. The estimated EPS for Q4 2024 was -0.54, which was a substantial decrease from the EPS surprise of 0.08 in the previous quarter (Q3 2024). Similarly, the estimated revenue for Q4 2024 was $16.5 million, whereas the revenue surprise in Q3 2024 was -1.35 million. This suggests that the company's performance was expected to worsen in Q4 2024, which could be a cause for concern for investors.